ストックスクリーナーアプリを入手
2.21
4.74%
0.10
プレマーケット:
2.33
0.12
+5.43%
Allogene Therapeutics Inc (ALLO) 最新ニュース
ALLO (Allogene Therapeutics) Investments And Advances : $111.82 Mil (As of Sep. 2024) - GuruFocus.com
Allogene stock touches 52-week low at $2 amid market challenges - Investing.com
Allogene's Q3 Loss Narrower Than Expected, Sales Nil - MSN
ALLOAllogene Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Allogene Therapeutics Announces Participation in December Investor Conferences - GlobeNewswire
Allogene Therapeutics to Present at Three Major Healthcare Conferences | ALLO Stock News - StockTitan
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - The Manila Times
Allogene Therapeutics Presents Preclinical Data for - GlobeNewswire
Allogene's Novel Dual CAR T ALLO-329 Shows Promise in Autoimmune Disease Study | ALLO Stock News - StockTitan
Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel - Marketscreener.com
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Declines By 5.8% - MarketBeat
Allogene halts enrollment in leukemia trial By Investing.com - Investing.com Australia
Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive™
Allogene halts enrollment in leukemia trial - Investing.com
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade - MarketBeat
Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace
Piper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00 - MarketBeat
Allogene shares target cut, rating held on trial enrollment issue By Investing.com - Investing.com UK
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
Allogene Therapeutics's SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com India
Allogene Therapeutics Q3 2024 Earnings Preview - MSN
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Allogene Therapeutics reports on CAR T therapy progress - Investing.com
Allogene Therapeutics (NASDAQ:ALLO) Given "Buy" Rating at HC Wainwright - MarketBeat
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlight - GuruFocus.com
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... - Yahoo Finance
Allogene Therapeutics: Q3 Earnings Snapshot - The Washington Post
Allogene Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewswire
Allogene Therapeutics Announces Positive Phase 1 Data - GlobeNewswire
Allogene's Cancer Drug Shows 50% Response Rate in Phase 1 Trial, Earns FDA Designation | ALLO Stock News - StockTitan
Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Allogene Therapeutics to Present New Data Demonstrating the - GlobeNewswire
Allogene's ALLO-316 Cancer Therapy Shows Promise: Key Trial Data Coming at Major Symposiums | ALLO Stock News - StockTitan
Vanguard Group Inc's Strategic Acquisition in Allogene Therapeutics Inc - GuruFocus.com
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.3%Still a Buy? - MarketBeat
Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World
Allogene Therapeutics Announces Participation in November Investor Conferences - StockTitan
Allogene Therapeutics’ (ALLO) “Buy” Rating Reiterated at HC Wainwright - Defense World
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Allogene Therapeutics (ALLO) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Allogene shares hold buy rating as FDA grants RMAT to ALLO-316 - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update - The Manila Times
FDA grants RMAT status to Allogene's kidney cancer therapy By Investing.com - Investing.com South Africa
FDA grants RMAT status to Allogene's kidney cancer therapy - Investing.com
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) - The Manila Times
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully - Yahoo Finance
Allogene Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6%Time to Buy? - MarketBeat
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):